IBT publishes annual report for 2018
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2018. The report is available on IBT’s website ibtherapeutics.com under the...
April 4, 2019
New Project Manager at IBT
IBT welcomes Patrick Beke as Project Manager. Patrick has an education in biomedical science and oncology. He has experience in academic research and managerial experience in primary patient...
January 17, 2018
IBT to present at Bio-Europe Spring 2017
Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, will present the company on Tuesday March 21, 2017...
March 1, 2017
Last patient enrolled in IBT’s Phase 2 study
Infant Bacterial Therapeutics AB (publ) (“IBT”) announces that the last premature infant has now been enrolled and recruitment to the Phase 2 study is now closed. The Phase 2 study...
January 24, 2017
IBT to present at 9th Annual Biotech Showcase 2017
Infant Bacterial Therapeutics AB (publ) (“IBT”), a pharmaceutical company that develops drugs that meet the medical needs of premature infants, will present the company on Wednesday...
December 15, 2016
Infant Bacterial Therapeutics AB appoints new CFO
Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of Daniel Mackey as Chief Financial Officer (CFO) from January 2017 replacing Michael Owens in this role....
October 12, 2016
IBT welcomes new Business Analyst
IBT welcomes Crescent Yingyue Liao as Business Analyst.
Crescent holds a Bachelor's degree in Biochemistry and a Master's degree in Bioentrepreneurship.
Read more IBT team here
September 2, 2016
New Vice President Clinical Development at IBT
IBT is welcoming Agneta Heierson as Vice President Clinical Development. She has over 25 years of experience working in the pharmaceutical industry. Most recently she has been the Global...
August 16, 2016
IBT’s rights issue fully subscribed
The result of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”) rights issue, for which the subscription period ended on 23 May 2016, indicates that 3,575,583 shares,...
May 26, 2016
IBT welcome new a Project Coordinator
IBT welcomes Jin-Yu Lu as Project Coordinator in Pharmaceutical Development. Jin has education in life science and bioentrepreneurship. She has experience in administrative and operational support...
January 21, 2016
New CFO at IBT
Michael Owens has joined IBT as Chief Financial Officer. Michael has a background as Auditor at Arthur Andersen & Co. and Ernst & Young AB. He has held the position as CFO at Vitamex AB and...
December 4, 2015
New addition to IBT Board of Directors
Margareta Hagman, M.B.A, was elected to the Board of Directors in the beginning of September. Margareta is working as CFO and Executive Vice President at BioGaia AB. Margareta has been at BioGaia...
September 24, 2015
IBT receives additional funding from BioGaia
Infant Bacterial Therapeutics plans to start a study on the safety and tolerability of the product in 2015. To allow for the study start, BioGaia will support IBT with an additional investment of 520...
March 26, 2015
Orphan Drug Designation in Europe
Infant Bacterial Therapeutics has now obtained the Orphan Drug Designation for Lactobacillus reuteri for the prevention of necrotizing enterocolitis in Europe.
Read the official press release here
February 23, 2015
New Head of Clinical Operations at IBT
Infant Bacterial Therapeutics is glad to welcome Tina Lorentzon as Head of Clinical Operations. Tina brings her extensive and rich experience in management of clinical trials within the...
February 2, 2015
New CCO at IBT
Sanjiv Sharma is joining Infant Bacterial Therapeutics as the new Chief Commercial Officer. Sanjiv brings to Infant Bacterial Therapeutics his long experience of launching companies and optimizing...
November 7, 2014
New CTO at IBT
Infant Bacterial Therapeutics is appointing Anders Kronström as Chief Technical Officer. Anders brings to the company significant experience from the pharmaceutical industry and will strengthen the...
October 20, 2014
New CMO at IBT
Infant Bacterial Therapeutics is welcoming Erik Kinnman as Chief Medical Officer. Erik will contribute with his extensive knowledge and experience from the pharmaceutical industry to the on-going...
August 22, 2014
New board member at IBT
Anders Ekblom is the latest addition to the Board of directors at Infant Bacterial Therapeutics. Anders has extensive experience as an executive and leader with broad business knowledge from senior...
April 11, 2014
FDA approves orphan drug designation
Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that affects premature infants. The FDA Office of Orphan Product Development has approved the request. Read the official press...
February 21, 2014
BioGaia invests in a drug against NEC
The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly...
February 21, 2014